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Human plasma kallikrein, a serine proteinase, plays a key role in
intrinsic blood clotting, in the kallikrein-kinin system, and in fibrin-
olysis. The proteolytic enzymes involved in these processes are usu-
ally controlled by specific inhibitors and may be influenced by several
factors including glycosaminoglycans, as recently demonstrated by
our group. The aim of the present study was to investigate the effect of
glycosaminoglycans (30 to 250 µg/ml) on kallikrein activity on plas-
minogen and factor XII and on the inhibition of kallikrein by the
plasma proteins C1-inhibitor and antithrombin. Almost all available
glycosaminoglycans (heparin, heparan sulfate, bovine and tuna der-
matan sulfate, chondroitin 4- and 6-sulfates) reduced (1.2 to 3.0 times)
the catalytic efficiency of kallikrein (in a nanomolar range) on the
hydrolysis of plasminogen (0.3 to 1.8 µM) and increased (1.9 to 7.7
times) the enzyme efficiency in factor XII (0.1 to 10 µM) activation.
On the other hand, heparin, heparan sulfate, and bovine and tuna
dermatan sulfate improved (1.2 to 3.4 times) kallikrein inhibition by
antithrombin (1.4 µM), while chondroitin 4- and 6-sulfates reduced it
(1.3 times). Heparin and heparan sulfate increased (1.4 times) the
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Plasma prekallikrein is a protein that cir-
culates in blood as the zymogen of human
plasma kallikrein (huPK). Kallikrein may be
involved in several physiological pathways
such as activation of factor XII (1) and plas-
minogen by direct cleavage of the zymogen
(2) or by activation of pro-urokinase (3).
The participation of huPK in physiologi-
cal processes requires the existence of sev-
eral controlling factors. Specific proteins have
been found to inhibit huPK activity. On the
other hand, biological compounds in contact
with circulating proteinases such as plasma
kallikrein are thought to affect their activity
(4,5). The glycosaminoglycans (GAGs) are
macromolecules present in blood vessels,
which may interfere with kallikrein activity
or inhibition (6,7). Recently we demonstrated
that GAGs affect the action of huPK on
kininogen hydrolysis and inflammation (8).
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In the present study, we report on the influ-
ence of some GAGs on other processes in
which huPK participates such as plasmino-
gen and factor XII activation, and on huPK
inactivation by the physiological inhibitors
C1-inhibitor and antithrombin.
The effect of GAGs on plasminogen
activation by huPK was studied by deter-
mining plasmin activity on a synthetic sub-
strate. Briefly, 3.1 nM huPK (8) in 50 mM
tris(hydroxymethyl)aminomethane (Tris)
buffer, pH 7.4, 12 mM NaCl, with or without
30  µg/ml GAGs (9), was incubated with
plasminogen (0.3 to 1.8 µM) for 2 h at 37ºC
as described (2). The chromogenic peptide
H-D-valyl-leucyl-lysine p-nitroanilide (H-D-
Val-Leu-Lys-pNan, 0.56 mM) was used to
monitor plasmin activity. Plasmin genera-
tion corresponds to hydrolyzed plasminogen
and its concentration was determined by com-
parison to the initial velocities of reaction
using commercial plasmin as standard (data
not shown). The catalytic parameters (KM
and kcat) calculated for plasminogen hydroly-
sis in the absence of any GAGs agreed with
those reported by others (2). Bovine derma-
tan sulfate, chondroitin 4-sulfate, chondroitin
6-sulfate, tuna dermatan sulfate and heparan
sulfate reduced the catalytic efficiency of
huPK from 63 to 16%, while heparin was the
only GAG that increased this hydrolysis
(44%), as shown in Table 1.
The contact activation system of human
plasma forms a complex surface involving
factor XII, prekallikrein and high molecular
weight kininogen. In this complex, prekalli-
krein is activated to kallikrein, which acti-
vates factor XII. The active form of factor
XII (factor XIIa) anchored to high molecular
weight kininogen is able to activate more
prekallikrein in an autocatalytic cycle. Since
factor XII is a natural substrate for huPK, we
studied the influence of GAGs on this inter-
action. Human plasma kallikrein (10 nM) in
50 mM Tris buffer, pH 7.4, 12 mM NaCl,
1 mg/ml bovine serum albumin (BSA), with
or without 100 µg/ml GAGs, was incubated
for 20 min at 37ºC with factor XII (0.1 to 10
µM). H-D-prolyl-phenylalanyl-arginine p-ni-
troanilide (H-D-Pro-Phe-Arg-pNan, 0.4 mM)
with 0.2 µM soybean trypsin inhibitor (SBTI),
that completely inhibited kallikrein, and 10
Table 1. Effect of glycosaminoglycans (GAGs) on the hydrolysis of plasminogen and factor XIIa by human
plasma kallikrein (huPK).
GAGs Plasminogen Factor XIIa
kcat KM kcat/KM kcat KM kcat/KM
(10-4 s-1) (µM) (102 M-1 s-1) (10-3 s-1) (µM) (102 M-1 s-1)
Control 3.35 ± 0.01 0.60 ± 0.01 5.58 1.00 ± 0.05 2.36 ± 0.31 4.24
Hep 23.3 ± 1.8 2.90 ± 0.34 8.04 17.6 ± 0.7 5.38 ± 0.29 32.7
HS 4.17 ± 0.07 0.89 ± 0.04 4.69 2.14 ± 0.12 2.64 ± 0.31 8.11
BDS 11.1 ± 0.5 5.35 ± 0.30 2.08 0.76 ± 0.03 0.33 ± 0.04 23.0
TDS 3.83 ± 0.17 0.91 ± 0.09 4.21 0.85 ± 0.02 0.35 ± 0.03 24.3
C4S 11.1 ± 0.5 5.35 ± 0.30 2.08 0.53 ± 0.02 0.61 ± 0.03 8.69
C6S 3.42 ± 0.05 1.25 ± 0.03 2.74 1.15 ± 0.02 0.59 ± 0.03 19.5
huPK (3.1 nM) in 50 mM Tris buffer, pH 7.4, 12 mM NaCl, with or without 30 µg/ml GAGs, was incubated
with plasminogen (0.3 to 1.8 µM) for 2 h at 37ºC. H-D-Val-Leu-Lys-pNan (0.56 mM) was used to monitor
plasmin activation (absorbance at 405 nm). huPK (10 nM) in 50 mM Tris buffer, pH 7.4, 12 mM NaCl, 1 mg/ml
BSA, with or without 100 µg/ml GAGs, was incubated for 20 min at 37ºC with factor XII (0.1 to 10 µM). H-D-
Pro-Phe-Arg-pNan (0.4 mM) with 0.2 µM SBTI and 10 µg/ml Polybrene were used to monitor factor XIIa
activation (absorbance at 405 nm). BDS = bovine dermatan sulfate; C4S = chondroitin 4-sulfate; C6S =
chondroitin 6-sulfate; Hep = heparin; HS = heparan sulfate; TDS = tuna dermatan sulfate. Data are reported
as means ± SEM.
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µg/ml Polybrene that prevented continued
factor XII activation, were added and the
activity of formed factor XIIa was evaluated
by hydrolysis of chromogenic peptide by
measuring absorbance at 405 nm (10). The
concentration of formed factor XIIa, and
hence of hydrolyzed factor XII, was deter-
mined by comparison to the velocities of
reaction of known concentrations of factor
XIIa. The KM and kcat values for the hydroly-
sis of factor XII by huPK in the absence of
GAGs were determined to be 2.36 µM and
1.00 x 10-3 s-1, respectively, as shown in
Table 1. Heparin, tuna dermatan sulfate, bo-
vine dermatan sulfate, chondroitin 6-sulfate,
chondroitin 4-sulfate and heparan sulfate
markedly increased (1.9 to 7.7 times) the
catalytic efficiency of the enzyme on factor
XII activation.
In order to study the effect of GAGs on
huPK inhibition, a kinetic assay was per-
formed based on a method described previ-
ously (6,11). The proteinase inhibitors C1-
inhibitor or antithrombin (12) with or with-
out GAGs were preincubated in 50 mM Tris
buffer, pH 8.0, 150 mM NaCl at 37ºC for 5
min. After this period, pre-warmed huPK at
final concentrations of 72-86 nM was added
to the reactions, and 50-µl aliquots were
removed at various times (0 to 20 min).
Residual enzyme activity was assessed on
the hydrolysis of the chromogenic substrate
N-α-acetyl-phenylalanyl-arginine p-nitroan-
ilide (Ac-Phe-Arg-pNan, 0.7 mM), moni-
tored at 405 nm. The kinetics of huPK inhi-
bition was studied with the inhibitors in 2- to
65-fold molar excess and each rate constant
was determined twice. The straight lines ob-
tained when natural logarithm of huPK re-
sidual activity was plotted versus time indi-
cate a pseudo-first-order kinetic. The values
of the apparent first-order rate constants (k)
were calculated from the slopes of those
lines and were found to be directly propor-
tional to the inhibitor concentrations - [I] -
(data not shown). The second-order rate con-
stants (k”) were calculated from the equa-
tion k = k” x [I].
The data showed a second-order rate con-
stant of 240 M-1 s-1 for kallikrein inhibition
by antithrombin, in agreement with a previ-
ous study (4); this rate, however, increased
about 3.4-fold in the presence of heparin
(Table 2). In addition, it was demonstrated
that antithrombin-mediated huPK inhibition
is enhanced by heparan sulfate and bovine
and tuna dermatan sulfate, and is impaired
by chondroitin 4- and 6-sulfates. Kallikrein
inhibition by C1-inhibitor was slightly in-
creased in the presence of GAGs (Table 2)
according to the calculated apparent second-
order rate constants.
The relationship between increased
iduronic acid and sulfate contents and the
enhancement of anticoagulant and antithrom-
botic activities has been established (13,14).
The dual action of the different GAGs on
huPK inactivation could be explained by
analyzing their carbohydrate composition. It
is known that GAGs contain iduronic acid
and sulfate. Our results showed that chon-
Table 2. Second-order rate constants for the inac-
tivation of human plasma kallikrein (huPK) by anti-
thrombin and C1-inhibitor in the presence of gly-
cosaminoglycans (GAGs).
Antithrombin C1-inhibitor
(103 M-1s-1) (103 M-1s-1)
Control 0.240 ± 0.004 17.0 ± 0.1
Hep 0.810 ± 0.054 23.0 ± 0.6
HS 0.560 ± 0.038 22.0 ± 1.0
BDS 0.530 ± 0.013 20.0 ± 0.3
TDS 0.290 ± 0.024 19.0 ± 0.7
C4S 0.200 ± 0.002 18.3 ± 0.5
C6S 0.180 ± 0.014 18.0 ± 0.3
C1-inhibitor or antithrombin with or without GAGs
were preincubated in 50 mM Tris buffer, pH 8.0,
150 mM NaCl at 37ºC for 5 min. huPK (72-86 nM)
was added and 50-µl aliquots were removed at
various times (0 to 20 min). Residual enzyme
activity was assessed on the hydrolysis of Ac-
Phe-Arg-pNan (0.7 mM), monitored at 405 nm.
BDS = bovine dermatan sulfate (100 µg/ml); C4S
= chondroitin 4-sulfate (250 µg/ml); C6S = chon-
droitin 6-sulfate (200 µg/ml); Hep = heparin (60
µg/ml); HS = heparan sulfate (70 µg/ml); TDS =
tuna dermatan sulfate (100 µg/ml).
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droitin sulfate, which does not contain
iduronic acid, has no significant action on
huPK inhibition while bovine dermatan sul-
fate, that contains more iduronic acid than
tuna dermatan sulfate, increases the inhibi-
tion. Heparin and heparan sulfate, having
high sulfate content, also increase the inhibi-
tion.
The mechanism by which glycosami-
noglycans interfere with huPK activity and
inhibition is not understood. However, some
possible mechanisms have been postulated
by others (8,15): i) GAGs may bind to en-
zymes inducing a conformational change,
leading to a more or less active form; ii)
GAGs may bind to natural substrates or in-
hibitors, neutralizing their positive charges
and interfering with their hydrolysis or inhi-
bition.
It has been reported that some circulating
proteins such as factor XI contain structural
elements involved in the interactions with
GAGs (16). These elements include basic
amino acids that form positively charged
binding sites for the negatively charged GAGs
(17). Thrombin, however, comprises a more
complex binding region involving charged
residues that are not essentially adjacent to
each other in the primary amino acid se-
quence, but are close together in the cor-
rectly folded protein (18,19). Since huPK
shares high structural homology with factor
XI (20), it was not surprising to observe that
consensus sequences related to heparin bind-
ing sites are present in huPK.
The physiological role of the presumed
interactions between huPK, GAGs and natu-
ral substrates and inhibitors is not known.
However, since some GAGs such as derma-
tan sulfate have no deleterious effects on the
organism, they appear to be candidates for
therapeutic use in processes in which kal-
likrein participates such as fibrinolysis and
blood coagulation or in processes involving
uncontrolled huPK activity.
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